Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + carboplatin + paclitaxel vs placebo + carboplatin + paclitaxel in stage IV squamous NSCLC (first-line)
CTR20181611Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Pulmonary squamous cell carcinoma, sponsored by Hengrui Therapeutics. Started Sep 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20181611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181611.